Arbutus Biopharma (ABUS) announced new data from its IM-PROVE I Phase 2a clinical trial showing that six doses of imdusiran, the ...

On Friday, Vir Biotechnology, Inc. (NASDAQ:VIR) announced end-of-treatment data from Part B of the MARCH Phase 2 study ...

Arbutus Biopharma Corporation (NASDAQ: ABUS) has announced new data from its im-Prove I Phase 2a clinical trial (AB-729-201) showing significant progress in achieving a functional cure for patients ...

Patient dosing has begun in a phase 1 trial evaluating QXL138AM, a masked immunocytokine targeting CD138, in advanced solid ...

HBsAg levels less than 1000 IU/mL achieved functional cure in Cohort A1 of the IM-PROVE I Phase 2a clinical trial Overall, in Cohort A1, 25% of patients achieved functional ...

50% of patients (3/6) with baseline HBsAg <1000 IU/mL achieved a functional cure (defined as sustained HBsAg loss and HBV DNA ...

Vir Biotechnology (VIR) announced end-of-treatment data from Part B of the MARCH Phase 2 clinical study evaluating combinations of tobevibart ...

Arbutus has moved into Part 3 of this clinical trial which evaluates repeat dosing of AB-101 for 28 days in patients with cHBV and expects to report preliminary data in the first half of next year.

Any investors hoping to find a Pacific Rim - Equity fund might consider looking past Matthews India Fund (MINDX). MINDX carries a Zacks Mutual Fund Rank of 4 (Sell), which is based on various ...

Pregnancy can be safe for patients with chronic myeloid leukemia (CML), particularly if they are in treatment-free remission ...

Nammi Therapeutics has commenced the first in-human Phase I trial of QXL138AM by dosing the first subject for treating ...

Nammi Therapeutics begins patient dosing in phase 1 study of QXL138AM for advanced solid tumours and multiple myeloma: Los Angeles Monday, November 11, 2024, 13:00 Hrs [IST] Nammi ...